CASI News and Press, CASI Pharmaceuticals Inc. From 04/26/23

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS PR Newswire BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercial...

2023-04-10 13:05:20 ET Gainers: GlucoTrack ( GCTK ) +193% . Eloxx Pharmaceuticals ( ELOX ) +50% . Avalo Therapeutics ( AVTX ) +27% . TG Therapeutics ( TGTX ) +21% . Better Therapeutics ( BTTX ) +17% . Losers: Apollomics (...

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER PR Newswire BEIJING , March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therap...

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA PR Newswire ~ NMPA approved CB-5339 CTA for Multiple Myeloma indication ~ ~ Expected enrollment to begin in 2023 ~ ...

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION PR Newswire ROCKVILLE, Md. and BEIJING , Dec. 15, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ...

CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q3 GAAP EPS of -$0.38 beats by $0.08 . Revenue of $10.21M (+25.9% Y/Y) beats by $0.3M . For further details see: CASI Pharmaceuticals GAAP EPS of -$0.38 beats by $0.08, revenue of $10.21M beats by $0.3M...

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire ROCKVILLE, Md. and BEIJIN , Nov. 14, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing...

Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...

Casi Pharmaceuticals ( NASDAQ: CASI ) is selling its equity interest of 12.0098% in Juventas Biotechnology (Tianjin) to Shenzhen Jiadao Gongcheng Equity Investment Fund for RMB240.87M (~$34.03M). Casi's unit Casi Biopharmaceuticals (Wuxi) signed the...

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET PR Newswire ROCKVILLE, Md. and BEIJING , Sept. 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on devel...